Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
The DOI matches its Crossref record; 220 of the 221 references it cites were found in a registry or an index.
Abstract
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation. In the era of first-generation antipsychotics, 4 clinical features characterized drug-induced SP: rapid relapse after drug discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and aripiprazole). These studies show that the prevalence rates of SP remain high in schizophrenia (30%) and higher (70%) in treatment-resistant schizophrenia. We then present neurobehavioral findings on antipsychotic-induced supersensitivity to dopamine from animal studies. Next, we propose criteria for SP, which describe psychotic symptoms and co-occurring movement disorders more precisely. Detection of mild/borderline drug-induced movement disorders permits early recognition of overblockade of D2 receptors, responsible for SP and TD. Finally, we describe 3 antipsychotic withdrawal syndromes, similar to those seen with other CNS drugs, and we propose approaches to treat, potentially prevent, or temporarily manage SP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but concerns [13] have remained about supersensitivity psychosis [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“In the era of first-generation antipsychotics (FGAs) both supersensitivity psychosis and tardive dyskinesia were widely studied [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“Although not widely recognized, withdrawal symptoms can occur on the cessation of both first- and second-generation antipsychotics (FGAs and SGAs).17,20,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Chouinard et al. [9] described withdrawal reactions due to antipsychotics dose decrease, discontinuation, or switch and concluded that acute withdrawal symptoms, rebound, and persistent post-withdrawal disorders may occur”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–220 of 220
Chesi, A. J. R., Feasey‐Truger, K. J., Alzheimer, C., & ten Bruggencate, G. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb01043.x · Cited by 14
McGuinness, S. M., Johansson, R. G., Lundstrom, J., et al. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00105-2 · Cited by 14
Kimura, H., Kanahara, N., Watanabe, H., & Iyo, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.008 · Cited by 14
Self-citationHigh neuroleptic plasma levels in patients manifesting supersensitivity psychosis.
Chouinard, G., Creese, I., Boisvert, D., Annable, L., Bradwejn, J., & Jones, B. (1982) · PubMed · Cited by 14
Self-citationIneffectiveness of deanol in tardive dyskinesia: A placebo controlled study
de Montigny, C., Chouinard, G., & Annable, L. (1979) · Psychopharmacology · doi:10.1007/bf00492207 · Cited by 13
Self-citationTsuboi, T., Suzuki, T., Bies, R. R., Remington, G., Pollock, B. G., Mimura, M., & Uchida, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.03.025 · Cited by 13
Discontinuing Paroxetine: A Personal Account
Shoenberger, D. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063650 · Cited by 12
Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis
Sultan, S., Chouinard, G., & Beaudry, P. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90031-b · Cited by 11
Self-citationJuarez-Reyes, M., Shumway, M., Battle, C. L., Bacchetti, P., Hansen, M. S., & Hargreaves, W. A. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(96)00130-3 · Cited by 11
Supersensitivity Psychosis and Its Response to Asenapine in a Patient with Delusional Disorder
Rajkumar, R. P. (2014) · Case Reports in Psychiatry · doi:10.1155/2014/215732 · Cited by 11
Formulation, Evaluation and Optimization of Asenapine Maleate Fast Mouth Dissolving Film
Kokare, C., Tagalpallewar, A. A., Aragade, P. S., et al. (2015) · Journal of Pharmaceutical Sciences and Pharmacology · doi:10.1166/jpsp.2015.1062 · Cited by 11
A Rating Scale for Psychotic Symptoms (RSPS):
Chouinard, G., & Miller, R. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00013-4 · Cited by 11
Self-citationA ten-year follow-up study of supersensitivity psychosis
Chouinard, G. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90231-p · Cited by 9
Self-citationDopamine D2High receptors moderately elevated by sertindole
Seeman, P. M. (2008) · Synapse · doi:10.1002/syn.20498 · Cited by 7
Factors affecting the course of tardive dyskinesia: A ten year follow up study
Chouinard, G., Annable, L., Ross‐Chouinard, A., & Holobow, N. E. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)91817-9 · Cited by 4
Self-citationDrugs of abuse and psychiatric disorders: Neurobiological and clinical aspects
Samaha, A., & Potvin, S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.03.012 · Cited by 3
Self-citationEuropean court upholds UK ban on Halcion
Dyer, C. (1999) · BMJ · doi:10.1136/bmj.318.7181.418a · Cited by 3
Goldstein, J., & Macfadden, W. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106231.36344.f8 · Cited by 2
2804 – Asenapine After Clozapine: Is Possible?
Matteo, P., Mula, M., Basaglia, C., et al. (2013) · European Psychiatry · doi:10.1016/s0924-9338(13)77392-9 · Cited by 1
Research works printed but not linked: 1
- 10.2165/1120086-000000000-00000 · doi:10.2165/1120086-000000000-00000
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
“…D2 receptors which has been held to be potentially responsible for breakthrough psychotic relapse in people with schizophrenia on maintenance antipsychotic medication as well as rebound psychosis after abruptly stopping treatment (Chouinard, 1991; Chouinard et al., 2017; Kimura et al., 2016).”
BackgroundPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
“2a).(33,37) In turn, increases in antipsychotic medication doses to control breakthrough symptoms are thought to lead to further increases in DRD2 density, resulting in increased dopamine supersensitivity, and consequently, the reemergence of symptoms.”
BackgroundResultInfluentialAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide
Montastruc, F., Nie, R., Loo, S., Rej, S., Dell’Aniello, S., Micallef, J., Suissa, S., & Renoux, C. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4149 · Cited by 179
Metadata
- Authors
- Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M.
- Affiliations
- Hôpital Saint-Antoine (FR)
- McLean Hospital (US)
- Chiba University (JP)
- ORCID
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 86
- Issue
- 4
- Pages
- 189-219
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2701376032
- Cited by
- 270
- References
- 221
- Citations by year
- 2026: 29 · 2025: 19 · 2024: 32 · 2023: 36 · 2022: 29 · 2021: 39 · 2020: 29 · 2019: 37 · 2018: 17 · 2017: 3
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K10266)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dopamine receptor supersensitivity, tardive dyskinesia, treatment-resistant schizophrenia, psychotic relapse, atypical antipsychotics, long-acting injectable antipsychotics, prolactin, drug-induced movement disorders
- MeSH terms
- Brain, Dopamine, Humans, Psychoses, Substance-Induced, Antipsychotic Agents, Receptors, Dopamine D2, Dopamine D2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.